<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263207</url>
  </required_header>
  <id_info>
    <org_study_id>ISS OBS T-005</org_study_id>
    <nct_id>NCT04263207</nct_id>
  </id_info>
  <brief_title>Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir</brief_title>
  <acronym>ISS OBS T-005</acronym>
  <official_title>Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ensoli, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A longitudinal observational study in HIV-infected subjects receiving cART addressed to
      explore the effect of the Tat protein and anti-Tat immunity on the formation and maintenance
      of HIV-1 virus reservoir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a longitudinal observational study addressed to identify the effects
      of Tat protein and humoral/cellular anti-Tat immune responses (induced in the natural
      infection or by Tat vaccination) in HIV-1 reservoir dynamics in blood of HIV infected
      patients receiving cART. HIV DNA data will be used for analyzing the decay dynamics.

      The primary objective of the study is to determine the rate of decay of total HIV DNA in
      blood of anti-Tat antibody (Ab) positive versus anti-Tat Ab negative HIV patients receiving
      cART.

      The secondary objectives of the study are to relate the HIV DNA decay data to:

        1. the persistence of anti-Tat humoral responses;

        2. biomarkers of HIV reservoir stability potentially affected by the Tat protein or
           anti-Tat immune responses, including: i) apoptotic/survival index of CD4+ T cells; ii)
           reactivation dynamics of latent HIV in resting CD4+ T cells upon exposure to Tat protein
           and/or activation stimuli; iii) cellular and humoral biomarkers relevant to inflammation
           and immune dysregulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV proviral DNA levels</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Changes of total HIV-1 proviral DNA copies/1.000.000 CD4+ T-cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV plasma viremia</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Changes of HIV plasma viral load (copies/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ and CD8+ T-cell levels</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Changes of CD4+ and CD8+ T-cell counts (cells/microL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lymphocytes subset apoptosis</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Apoptotic index of isolated lymphocytes subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of replication of competent latent HIV-1 from resting CD4+ T-cell</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Quantification of replication competent latent HIV-1 from isolated resting CD4+ T cells [TZM-bl cell based assay (TZA)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation/immune activation biomarkers</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Plasma levels of inflammation and immune activation biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Tat Ab isotypes</measure>
    <time_frame>Baseline and through study completion, an average of 3 years</time_frame>
    <description>Anti-Tat humoral response in terms of anti-Tat IgM, IgG and IgA Ab</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>anti-Tat Ab positive subjects</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-Tat Ab negative subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>anti-Tat Ab negative subjects</arm_group_label>
    <arm_group_label>anti-Tat Ab positive subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Periferal blood mononuclear cells and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected adult subjects of either gender, ≥18 years old, under cART, with CD4+ T-cell
        count ≥250 cells/µL.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Diagnosis of HIV-1 infection

          3. To be under cART treatment

          4. CD4+ T-cell count ≥250 cells/microliters

          5. Testing for anti-Tat Ab performed during pre-screening

          6. Signed informed consent

        Exclusion Criteria:

        1. Current therapy with immunomodulators or immunosuppressive drugs or chemotherapy for
        neoplastic disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Ensoli, M.D. Ph.D</last_name>
    <phone>+39 06 4990</phone>
    <phone_ext>3209</phone_ext>
    <email>barbara.ensoli@iss.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Dermatology STI Unit San Gallicano Dermatologic Institute , IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Latini, M.D.</last_name>
      <phone>+39 065266</phone>
      <phone_ext>2805</phone_ext>
      <email>alessandra.latini@ifo.gov.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Murray AJ, Kwon KJ, Farber DL, Siliciano RF. The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. J Immunol. 2016 Jul 15;197(2):407-17. doi: 10.4049/jimmunol.1600343. Review.</citation>
    <PMID>27382129</PMID>
  </reference>
  <reference>
    <citation>Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, Viard JP, Rouzioux C. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin Microbiol Rev. 2016 Oct;29(4):859-80. doi: 10.1128/CMR.00015-16. Review.</citation>
    <PMID>27559075</PMID>
  </reference>
  <reference>
    <citation>Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, Quinn TC, Siliciano RF. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000 Dec;182(6):1636-42. Epub 2000 Nov 8.</citation>
    <PMID>11069234</PMID>
  </reference>
  <reference>
    <citation>Siliciano JM, Siliciano RF. The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells. J Infect Dis. 2015 Nov 1;212(9):1345-7. doi: 10.1093/infdis/jiv219. Epub 2015 Apr 15.</citation>
    <PMID>25877551</PMID>
  </reference>
  <reference>
    <citation>Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.</citation>
    <PMID>25924841</PMID>
  </reference>
  <reference>
    <citation>Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011 Aug 17;477(7362):95-8. doi: 10.1038/nature10347.</citation>
    <PMID>21849975</PMID>
  </reference>
  <reference>
    <citation>Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016 Feb 4;530(7588):51-56. doi: 10.1038/nature16933. Epub 2016 Jan 27.</citation>
    <PMID>26814962</PMID>
  </reference>
  <reference>
    <citation>Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015 Jan 15;517(7534):381-5. doi: 10.1038/nature14053. Epub 2015 Jan 7.</citation>
    <PMID>25561180</PMID>
  </reference>
  <reference>
    <citation>Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF. Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med. 2017 Apr 3;214(4):959-972. doi: 10.1084/jem.20170193. Epub 2017 Mar 24.</citation>
    <PMID>28341641</PMID>
  </reference>
  <reference>
    <citation>Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001 Apr 2;20(7):1726-38.</citation>
    <PMID>11285236</PMID>
  </reference>
  <reference>
    <citation>C Quaresma AJ, Bugai A, Barboric M. Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. Nucleic Acids Res. 2016 Sep 19;44(16):7527-39. doi: 10.1093/nar/gkw585. Epub 2016 Jul 1. Review.</citation>
    <PMID>27369380</PMID>
  </reference>
  <reference>
    <citation>Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005 Jul 29;122(2):169-82.</citation>
    <PMID>16051143</PMID>
  </reference>
  <reference>
    <citation>Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. A hardwired HIV latency program. Cell. 2015 Feb 26;160(5):990-1001. doi: 10.1016/j.cell.2015.02.009.</citation>
    <PMID>25723172</PMID>
  </reference>
  <reference>
    <citation>Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B. &quot;cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies&quot;. Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.</citation>
    <PMID>29243498</PMID>
  </reference>
  <reference>
    <citation>Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988 Dec 23;55(6):1189-93.</citation>
    <PMID>2849510</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993 Jan;67(1):277-87.</citation>
    <PMID>8416373</PMID>
  </reference>
  <reference>
    <citation>Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. mBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.</citation>
    <PMID>26152583</PMID>
  </reference>
  <reference>
    <citation>Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, Ho PT, Honeycutt JB, Fallahi M, Trautmann L, Garcia JV, Valente ST. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a &quot;Block-and-Lock&quot; Strategy for HIV-1 Treatment. Cell Rep. 2017 Oct 17;21(3):600-611. doi: 10.1016/j.celrep.2017.09.080.</citation>
    <PMID>29045830</PMID>
  </reference>
  <reference>
    <citation>Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13588-93. doi: 10.1073/pnas.1308673110. Epub 2013 Jul 29.</citation>
    <PMID>23898208</PMID>
  </reference>
  <reference>
    <citation>López-Huertas MR, Mateos E, Sánchez Del Cojo M, Gómez-Esquer F, Díaz-Gil G, Rodríguez-Mora S, López JA, Calvo E, López-Campos G, Alcamí J, Coiras M. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem. 2013 Mar 15;288(11):7626-44. doi: 10.1074/jbc.M112.408294. Epub 2013 Jan 30.</citation>
    <PMID>23364796</PMID>
  </reference>
  <reference>
    <citation>Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Mazzoni M, Capitani S. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood. 1995 Nov 15;86(10):3823-34.</citation>
    <PMID>7579350</PMID>
  </reference>
  <reference>
    <citation>Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B, Federico M. Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. AIDS. 2014 Sep 24;28(15):2189-200. doi: 10.1097/QAD.0000000000000389.</citation>
    <PMID>25313583</PMID>
  </reference>
  <reference>
    <citation>Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Buttò S, Ensoli B. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis. 2005 Apr 15;191(8):1321-4. Epub 2005 Mar 14.</citation>
    <PMID>15776379</PMID>
  </reference>
  <reference>
    <citation>Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.</citation>
    <PMID>24961156</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.</citation>
    <PMID>21085635</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.</citation>
    <PMID>27277839</PMID>
  </reference>
  <reference>
    <citation>Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999 May;5(5):512-7.</citation>
    <PMID>10229227</PMID>
  </reference>
  <reference>
    <citation>Sanyal A, Mailliard RB, Rinaldo CR, Ratner D, Ding M, Chen Y, Zerbato JM, Giacobbi NS, Venkatachari NJ, Patterson BK, Chargin A, Sluis-Cremer N, Gupta P. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4(+) T cells. Nat Med. 2017 Jul;23(7):885-889. doi: 10.1038/nm.4347. Epub 2017 May 29.</citation>
    <PMID>28553933</PMID>
  </reference>
  <reference>
    <citation>Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.</citation>
    <PMID>23152803</PMID>
  </reference>
  <reference>
    <citation>Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B, Toschi E, Ensoli B. Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Int J Vasc Med. 2011;2011:452729. doi: 10.1155/2011/452729. Epub 2011 Oct 9.</citation>
    <PMID>22007303</PMID>
  </reference>
  <reference>
    <citation>Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B. Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.</citation>
    <PMID>30815001</PMID>
  </reference>
  <reference>
    <citation>Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Buttò S, Monini P, Ensoli B. Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines (Basel). 2019 Aug 26;7(3). pii: E99. doi: 10.3390/vaccines7030099. Review.</citation>
    <PMID>31454973</PMID>
  </reference>
  <reference>
    <citation>Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B. HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Rev Vaccines. 2020 Jan;19(1):71-84. doi: 10.1080/14760584.2020.1712199. Epub 2020 Jan 19.</citation>
    <PMID>31957513</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Barbara Ensoli, MD, PhD</investigator_full_name>
    <investigator_title>Director, National HIV/AIDS Research Center (CNAIDS)</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Immune responses</keyword>
  <keyword>Tat</keyword>
  <keyword>HIV reservoire</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

